What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
暂无分享,去创建一个
Jarno Hoekman | Marcel H N Hoefnagel | Gerty Schreibelt | Anke M Hövels | Renske M T Ten Ham | Geert W J Frederix | Hubert G M Leufkens | Olaf H Klungel | Inge Jedema | Sabrina A J Veld | Tatjana Nikolic | Melissa Van Pel | Jaap J Zwaginga | Fong Lin | Anna L de Goede | Sandy Budde | I Jolanda M de Vries | Gwen M Wilkie | Harry Dolstra | Hans Ovelgönne | Pauline Meij | Joanne C Mountford | Marc L Turner | J. Hoekman | H. Leufkens | M. Turner | O. Klungel | J. Zwaginga | G. Frederix | T. Nikolić | H. Dolstra | A. Hövels | I. D. de Vries | M. Hoefnagel | J. Mountford | M. van Pel | I. Jedema | G. Schreibelt | P. Meij | H. Ovelgönne | G. Wilkie | A. D. de Goede | S. Veld | R. M. ten Ham | F. Lin | Sandy Budde | R. M. Ten Ham | I. de Vries | Joanne C. Mountford | Hubert G.M. Leufkens | Jaap J. Zwaginga | Anke M. Hövels | Olaf H. Klungel | Gwen M. Wilkie | Marc L. Turner | Marcel H.N. Hoefnagel | R. T. Ten Ham | I. J. M. de Vries | H. Leufkens
[1] K. Lennerts,et al. A process‐oriented analysis of facility management services in hospitals as a basis for strategic planning , 2009 .
[2] R. W. Hansen,et al. Journal of Health Economics , 2016 .
[3] A. Webster,et al. Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK. , 2018, Regenerative medicine.
[4] P. Moutsatsou,et al. Automation in cell and gene therapy manufacturing: from past to future , 2019, Biotechnology Letters.
[5] Angel Nuñez,et al. Acute exercise does not modify brain activity and memory performance in APP/PS1 mice , 2017, PloS one.
[6] P. Auquier,et al. Funding breakthrough therapies: A systematic review and recommendation. , 2017, Health policy.
[7] Volker Huppert,et al. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure , 2016, Journal of Translational Medicine.
[8] P. Reinke,et al. Overcoming Challenges Facing Advanced Therapies in the EU Market. , 2016, Cell stem cell.
[9] Mariele Viganò,et al. Challenges of running a GMP facility for regenerative medicine in a public hospital. , 2017, Regenerative medicine.
[10] D. Rind,et al. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] T. Wirth,et al. History of gene therapy. , 2013, Gene.
[12] A. Haycox,et al. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways , 2016, Front. Pharmacol..
[13] E K Mensah,et al. Distribution of variable vs fixed costs of hospital care. , 1999, JAMA.
[14] Gert Jan van der Wilt,et al. Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. , 2016, Clinical chemistry.
[15] Bob Löwenberg,et al. Sustainability and affordability of cancer drugs: a novel pricing model , 2018, Nature Reviews Clinical Oncology.
[16] Daniel Kaiser,et al. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. , 2013, Cytotherapy.
[17] J. Hoekman,et al. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe , 2018, Molecular therapy. Methods & clinical development.
[18] F. Rutten,et al. UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS , 2012, International Journal of Technology Assessment in Health Care.
[19] I. Slaper-Cortenbach,et al. Current status of JACIE accreditation in Europe: a special report from the Joint Accreditation Committee of the ISCT and the EBMT (JACIE) , 2007, Bone Marrow Transplantation.
[20] H. Guchelaar,et al. Clinical development of gene- and cell-based therapies: overview of the European landscape , 2016, Molecular therapy. Methods & clinical development.
[21] Q. She,et al. CRISPR History: Discovery, Characterization, and Prosperity. , 2017, Progress in molecular biology and translational science.
[22] H. Guchelaar,et al. Development of cell therapy medicinal products by academic institutes. , 2016, Drug discovery today.
[23] Mohan V. Tatikonda,et al. Vector production in an academic environment: a tool to assess production costs. , 2013, Human gene therapy methods.
[24] F. Rutten,et al. Comparing methodologies for the cost estimation of hospital services , 2009, The European Journal of Health Economics.
[25] B. Sharrack,et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.
[26] F. Belardelli,et al. Translational research on advanced therapies. , 2011, Annali dell'Istituto superiore di sanita.
[27] W. V. van Harten,et al. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation , 2018, BMC Cancer.
[28] J. Ratcliffe,et al. Economic Evaluation of Stem Cell Therapies in Neurological Diseases: A Systematic Review. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] A. Faulkner,et al. Are there specific translational challenges in regenerative medicine? Lessons from other fields. , 2015, Regenerative medicine.
[30] L. Naldini,et al. Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products , 2017, EMBO molecular medicine.
[31] Anand M. Prabhakar,et al. Time-driven activity-based costing trumps traditional cost accounting for radiologists. , 2015, AJR. American journal of roentgenology.
[32] P. Kefalas,et al. Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test , 2017, Journal of market access & health policy.
[33] B. Baradaran,et al. Gene therapy, early promises, subsequent problems, and recent breakthroughs. , 2013, Advanced pharmaceutical bulletin.